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OBJECTIVE: To study the longitudinal relationship of limited joint mobility (LJM) 
expression, severity and evolution with glycemic control and to determine its association with 
retinopathy and albuminuria in type 1 diabetic patients.  
 
RESEARCH DESIGN AND METHODS: A total of 26 type 1 diabetic adolescents aged 13-
18 years and with a disease duration ≥ 5 years were prospectively followed between 2007-2013 
with repeated measurements of HbA1c levels and assessments of retinopathy and albuminuria. 
Retrospective HbA1c levels were also obtained. LJM was accessed twice, once in 2007 and 
again in 2013.  
 
RESULTS: Overall prevalence of LJM was 85%. Prevalence of each LJM stage significantly 
changed between the two evaluations (p=0.049); 69% of the patients showed a 
regression/maintained their initial stage while 31% progressed to a severer one. Progression 
group had higher mean HbA1c levels than the regression/no-evolution group (9.8 ± 1.3 vs 8.6 
± 1.2%, p=0.03). Patients with final stage ≥ 2 had higher mean HbA1c than stage-0 (9.9 ± 0.9 
vs 8.6 ± 0.7%, p=0.01) and than stage-1 patients (9.9 ± 0.9 vs 8.2 ± 0.9%, p=0.01). Both 
presence and evolution of LJM weren’t significantly associated with retinopathy and 
albuminuria.  
 
CONCLUSIONS: Severer stages and progression of LJM are associated with poorer glycemic 
control in adolescents and young adults with type 1 diabetes. Inclusion of LJM assessment in 
the follow-up routine should be considered, especially in these patients. Larger longitudinal 
studies with several evaluations of LJM are fundamental to evaluate more fully its clinical 
course and association with glycemic control and microvascular complications.  
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Type 1 Diabetes Mellitus is a chronic disease associated with significant morbidity not 
only due to the extensively known and studied micro and macrovascular complications but also 
due to its several rheumatic and musculoskeletal manifestations (1; 2). Among these 
manifestations the most frequent are those affecting the upper limb, specially the hands (2) and 
so the term “diabetic hand” has arisen, encompassing a range of conditions that affect the hands 
of diabetic patients including limited joint mobility (LJM) in first place but also Dupuytren's 
contracture, flexor tenosynovitis and others (3). 
LJM is the first clinically apparent long-term complication of type 1 diabetes (4). It 
affects primarily the hands and is characterized by painless, non-inflammatory limitation of 
extension of the finger joints in association with thick and waxy skin, particularly on their 
dorsal surface. The onset of LJM is insidious; it usually begins in the fifth finger and then 
progresses radially with hands being symmetrically affected in most of the cases. The first and 
most frequently limited joints are the proximal interphalangeal (PIP) and distal interphalangeal 
(DIP) joints; gradually, it can start to affect metacarpophalangeal (MCP) joints and, in later 
stages, may extend beyond the hands to peripheral large joints of both upper and lower limbs 
as wrists, elbows, knees, ankle and inclusive to spine (5-9). The diagnosis of this condition is 
essentially clinical and can be made with the help of two clinical signs: the “prayer sign” and 
the “tabletop test” (5; 7; 10). Laboratory, imaging, and nail fold capillaroscopy findings are 
usually unremarkable or nonspecific (5; 8).  
LJM was first reported as particularly associated with juvenile type 1 diabetes by 
Rosenbloom in 1974 (11) and it was only since then that larger studies on this topic started to 
be conducted, corroborating these findings (6; 8). The estimated prevalence of LJM among 
diabetic patients varies widely according to different authors, ranging from 8 to 58% in type 1 
diabetes (2) but it’s often suggested at between 30 and 40% by most studies (8). There is also 
significant evidence that the frequency of LJM increases with increasing diabetes duration (12-
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14), with pre-pubertal onset of diabetes (15) and with puberty (16), being more common 
between the ages of 10 and 20 and rare before the age of 10 (2; 4). Moreover, no gender or 
racial differences have been found (8; 10).  
The early recognition of this condition is important because there is some evidence that 
it is associated with poor glycemic control (13; 16; 17) and with diabetic microvascular 
complications (13; 14; 16; 18-20). However, most of the studies focused on these topics are 
cross-sectional, with only a few of them having a prospective design. Moreover, in most of the 
cases, results are conflicting and therefore many questions still with no conclusive answer. For 
instance, whether careful glycemic control can prevent the onset of LJM or improve/stabilize 
the LJM already established is unknown; similarly, the extent to which LJM serves as an early 
marker of ongoing retinopathy/nephropathy has not been conclusively determined (2; 8).  
The current study aims to determine the longitudinal relationship of LJM presence and 
severity with glycemic control in type 1 diabetic patients and to understand the extent to which 
the evolution of LJM depends on glycemic control. It also pretends to evaluate the association 
of LJM with retinopathy and albuminuria. 
 
RESEARCH DESIGN AND METHODS 
 
We conducted a longitudinal prospective study with beginning in 2007 and ending in 
2013, in a total of 6 years of follow-up.  
Consecutive type 1 diabetic patients were recruited from the pediatric endocrinology 
outpatient consultation of Centro Hospitalar São João during over a one year period. Patients 
must had a documented date of diabetes diagnosis and should be followed in this hospital’s 
consultation from soon after that time in order to have reliable retrospective data. Only patients 
aged between 13 and 18 and with a disease duration of 5 or more years were included. All the 
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other patients were excluded as well as those who had a history of hand injury, Dupuytren's 
contracture, flexor tenosynovitis or any other hand disorder that could misunderstood the 
evaluation of LMJ. With this criteria, we were able to recruit 46 patients into de study by 2007. 
However, due to hospital transfers or repeated absences to scheduled appointments, there were 
some subjects lost to follow-up which were excluded from the final sample. In the end, we 
counted with a total of 26 patients.  
Informations about patient’s age, duration of diabetes, age of diagnosis, HbA1c levels, 
status of retinopathy and albuminuria were recorded for each patient in 2007 first evaluation. 
All retrospective information needed was obtained from medical files. During the follow-up 
time, patients visited the hospital every two to four months in the context of their routine 
outpatient follow-up and updated informations about HbA1c levels, retinopathy and 
albuminuria status were also recorded.  
Joint mobility was only accessed twice, once in 2007 and again in 2013. There were no 
retrospective informations about it for any of the patients. The observer was the same for all 
patients within the same year but different between the two evaluations. Nevertheless, the 
exactly same methods were used and last examiner was blinded to previous results. The 
“tabletop test” and “prayer sign” were performed subsequently to assess joint mobility. The 
“prayer sign” was positive if the patient was unable to completely approximate the palmar 
surface of the hands and fingers when asked to raise the hands in a praying position with the 
fingers fanned and wrists extended (5; 18; 21). The “tabletop test” was positive if the patient 
was unable to make contact of the entire palmar surface to a table when asked to flatten the 
palm of his hand with the fingers fanned against the table’s surface (5; 8; 22). 
Metacarpophalageal joint contractures were detect by asking the patient to lift the palm from 
the table while keeping the fingers on it (15). When one or both of these maneuvers were 
positive, the examiner confirmed the limited mobility by attempting to extend the fingers 
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passively; there was a loss of passive extension if the range of extension was less than 180° at 
the PIP and DIP joints, less than 60° at the MCP joints and less than 70º at wrist (5; 7; 18).  
Joint mobility was staged from 0 to 3 based on the classification of Grgic et al. (22) - stage 0: 
entire palmer surface contacts with the table and there is no limitation; stage 1: only one finger 
of one or both hands is affected; stage 2: two or more fingers of each hand are affected; stage 
3: all fingers of both hands plus some larger joint (wrist) are affected. Comparing the first 
evaluation’s stage with the last one, patients were included in one of three groups: regression 
(if initial stage > last stage), no-evolution (if initial stage = last stage) and progression (if initial 
stage < last stage). Overall, patients were included in “with LJM” group if they presented 
limitation of joint mobility in any of the two evaluations; the remainder were included in 
“without LJM” group. 
Glycemic control was measured by HbA1c levels. All its retrospective determinations 
from soon after diagnosis of diabetes were recorded. During follow-up time, HbA1c levels were 
determined from blood samples taken during outpatient visits. At least two measurements were 
recorded per year per patient.  
Retinopathy status was determined annually by a trained ophthalmologist and considered 
to be present if it was diagnosed in any of its forms (non-proliferative or proliferative). 
Albuminuria status was determined by measurement of the albumin excretion and 
albumin/creatinine ratio (ACR) in random spot urine collections. A patient was considered to 
have developed increased urinary albumin excretion (Albuminuria+) only if more than two 
consecutive specimens collected were abnormal (ACR ≥30 mg/g creatinine) and were then 
confirmed by an abnormal 24h urine analyses ( ≥30 mg/24h). Both persistent albuminuria (at 
levels 30–299 mg/24h and levels >300 mg/24h) and transient albuminuria were included in the 
same category (23). Isolated abnormal ACR and 24h albumin excretion <30 mg/24 h were 
considered normal.  
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Ethical approval was obtained from ethical committee of the Centro Hospitalar São João. 
Adolescents were asked to assent before entering the study and oral informed consent was 
obtained from the parents prior to their inclusion. Written consent was also obtained from 
patients in the second LJM evaluation in 2013.  
 
Statistical analyses  
All continuous variables were accessed for their normality using Shapiro-Wilk normality 
test. Normally distributed data are expressed as means ± SE; otherwise the median (range) is 
used. Differences in normal continuous variables between groups were analyzed using the 
parametric tests Independent Samples T Test, Paired-Samples T Test or One-way ANOVA 
with Bonferroni correction for post-hoc testes when necessary. When parametric tests’ 
assumptions were not verified or variables didn’t follow a normal distribution, comparison 
between groups were done using non-parametric Mann Whitney U Test. Chi-square testing 
allowed comparisons between categorical variables. In some analysis, data from groups with 
LJM stages 2 and 3 as well as from regression and no-evolution group were combined.  IBM 
SPSS Statistics version 21 was used for analysis. A p-value <0.05 was considered significant.  
 
RESULTS 
 
Demographic and clinical characteristics of the sample 
A total of 26 patients (14 males and 12 females) with type 1 diabetes meeting the 
inclusion and follow-up criteria were included in the statistical analyses. Characteristics of the 
sample at the beginning of the study are shown in Table 1. The mean age of the patients was 
14.9 ± 1.6 years with a median duration of diabetes of 7.5 years (range 5-14). In terms of 
clinical characteristics, the mean HbA1c of the sample was 9.3 ± 1.4% (78 ± 15.3 mmol/mol); 
none of the patients had documented retinopathy at the time and just 2 had evidence of 
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albuminuria. All patients were followed during the 6-years period from 2007 to 2013. By the 
end of the study, all patients had already reached adulthood; the mean HbA1c was 9.1 ± 1.1% 
(76 ± 12.0 mmol/mol), retinopathy was present in 39% (n=10) of the patients and albuminuria 
in 27% (n=7).  
 
LJM prevalence, staging and evolution 
The prevalence of LJM (stage>0) in 2007 was 58% (n=15) compared with 70% (n=19) 
in 2013. The distribution of LJM stages significantly changed between the two evaluations: 
stage-0 prevalence decreased from 42 to 27%; stage-1 increased from 23 to 27%; stage-2 
increased from 19 to 35% and stage-3 decreased from 15 to 12% (p=0.049). Patients with the 
same initial stage showed different evolutions during the follow-up time, being able to present 
a less or a more severe final stage than the initial one (Figure 1). In a global view, 69% of 
patients showed a regression or maintained the initial stage while 31% progressed to a more 
severe one. The characteristics of each evolution group are listed in Table 2. The median 
diabetes duration, age as well as the gender distribution wasn’t statistically different between 
the two groups.  
By the end of the study, patients with LJM represented 85% (n=22) of the sample and 
those without LJM represented the remaining 15% (Table 3). As for the evolution groups, no 
differences in diabetes duration, age and gender distribution were observed between patients 
with and without LJM.  
 
 
Relation of LJM presence, evolution and severity to glycemic control 
Mean HbA1c levels during the follow-up period were significantly higher in those patients 
of the progression group compared to those of the regression/no-evolution group (9.8 ± 1.3 vs 
8.6 ± 1.2%, p=0.03) (84 ± 14.2 vs 70 ± 13.1 mmol/mol). Similar findings were observed within 
the groups of patients with the same initial stage: for a given initial stage, patients who 
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regressed to a less severe stage had lower mean HbA1c levels during the follow-up than those 
who maintained or progressed to a severer one; similarly, patients who maintained the same 
stage had lower levels than those who progressed (data not shown). However, these differences 
were not significant for any of the four initial stages. Using the mean of all HbA1c values 
recorded until 2013 instead of using those recorded only during the follow-up period, similar 
comparisons reached significance and revealed overlapping results: HbA1c levels were 
significantly higher in patients initially 0-staged that progressed to stage-1/stage-2 comparing 
with those who didn’t (10.1 ± 1.0 vs 8.7 ± 0.7%, p=0.04) (87 ± 10.9 vs 72 ± 7.7 mmol/mol) 
and in patients initially 2-staged who remained in that stage compared with those who regressed 
to a less severe stage (9.3 ± 0.3 vs 8.0 ± 0.3%, p=0.01) (78 ± 3.3 vs 64 ± 3.3 mmol/mol). These 
differences were also observed for initial stage-3 group but statistical conclusions were not 
possible due to small numbers.  
 Comparing the mean HbA1c levels until 2007 with the mean HbA1c levels during the 
follow-up period, in the regression/no-evolution group these values decreased from 9.1 ± 1.5 
to 8.6 ± 1.2% (76 ± 16.4 to 70 ± 13.1 mmol/mol) and in the progression group increased from 
9.5 ± 1.3 to 9.8 ± 1.2% (80 ± 14.2 to 84 ± 13.1 mmol/mol); however, these differences were 
not significant in any of the groups. Doing the same comparison between the two periods but 
taking into account the initial stage, patients who progressed from stage-0 to stage-1 or to stage-
2 had higher mean HbA1c values during the follow-up period compared to before (9.1 ± 0.1 vs 
8.4 ± 0.4%; 10.5 ± 1.3% vs 10.2 ± 1.0%, respectively) (76 ± 1.1 vs 68 ± 4.4 mmol/mol; 91 ± 
14.2 vs 88 ± 10.9 mmol/mol)  and patients who regressed from stage-1 to stage-0 had lower 
values during follow-up (7.8 ± 0.2 vs 9.1 ± 1.6%) (62 ± 2.2 vs 76 ± 17.5 mmol/mol) although 
differences didn’t reach significance; comparisons for other evolution pares were not possible 
due to the small numbers.  
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By the end of the study, mean HbA1c levels were higher in patients with LJM compared 
to those without LJM but the difference was not significant. No differences were found in 
HbA1c levels between males or females with or without LJM. Taking into account the severity 
of the final stage, in patients with final stage ≥ 2 the mean HbA1c for all disease duration was 
higher than in stage-0 patients (9.9 ± 0.9 vs 8.6 ± 0.7%, p=0.01) (85 ± 9.8 vs 70 ±7.7 mmol/mol) 
and than in stage-1 patients (9.9 ± 0.9% vs 8.2 ±0.9%, p=0.01) (85 ± 9.8 vs 66 ± 9.8 mmol/mol).   
 
Relation of LJM to retinopathy and albuminuria 
There was no difference in the prevalence of retinopathy and albuminuria between 
patients with and without LJM. This proportion was also not different between the progression 
and regression/no-evolution groups. The relative risk for the presence of microvascular 
complications showed no significant risk for patients with LJM: RR of retinopathy was 1.6 
(95% CI: 0.3-9.6) and RR of albuminuria 1.1 (95% CI: 0.2-6.8). 
 
CONCLUSIONS 
 
Musculoskeletal manifestations associated with type 1 diabetes are frequently under-
recognized and overlooked in spite of being quite common and responsible for substantial 
morbidity (5). LJM is usually asymptomatic and non-disabling but later in the course of the 
condition it can lead to fixed flexion contractures of the small hand joints, to decreased grip 
strength and to an impaired dexterity and ability to perform fine hand movements (7; 8; 10). 
However, the importance of LJM is not just related with the condition itself but also with its 
presumable association with glycemic control and microvascular complications. LJM 
pathogenesis can be postulated as the explanation for these associations. There is evidence that 
persistent hyperglycemia leads to non-enzymatic glycosylation of collagen resulting in 
accumulation of abnormal cross-linked collagens resistant to degradation that are responsible 
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for abnormal stiffening of the peri-articular soft tissue; these changes also lead to microvascular 
abnormalities and vascular ischemia, characteristic changes of diabetic microangiopathy (6; 8; 
10). This abnormal glycosylation may be reversible early in the course of the disease or 
decreased with improved glycemic control but become irreversible later, once cumulative 
damage to collagen has occurred (24).  
Overall prevalence of LJM in our study (85%) was a quite higher than that founded by 
other reports. We attribute this this fact to our definition of LJM and to some of our selection 
criteria once puberty, age and diabetes duration are associated with higher prevalence of LJM 
(12; 16). The current study detected any differences between genders. However, unlike the 
most of the studies, it didn’t also detect a significant increased prevalence of LJM with 
increasing age and diabetes duration, maybe due to the small range of age and diabetes duration 
of our sample.  
Most of the cross-sectional studies have shown no association between LJM and the 
presence of higher HbA1c levels (12; 25-27) but longitudinal studies have confirmed this 
relation, indicating that the lack of association maybe was due to the use of only a single HbA1c 
value (13; 16; 17; 28). Moreover, two studies in type 1 diabetic patients have shown a decrease 
in LJM prevalence during a two decades interval, what was attributed to more intensive 
treatment strategies and improved glycemic control (12; 29). In our study, mean HbA1c levels 
were higher in patients with LJM but, in contrast to the referred longitudinal studies, this result 
wasn’t significant probably due to the small number of our sample. However, when different 
stages of severity were considered, poor glycemic control was significantly associated with the 
most severe stages of LJM (stages ≥ 2) while other patients had a proved better glycemic 
control. These findings are in agreement with other studies where LJM severity was considered 
(13; 16). Thus, and considering the reduction in the number of cases with moderate to severe 
joint limitation also found along with the decrease in LJM prevalence (12; 29), we can 
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hypothesize that differentiation between different stages of LJM severity might be as or more 
important than the presence/absence of LJM when considering the role of glycemic control.  
Faced with the observation that different patients had a different evolution of their joint 
mobility during the follow-up period, we hypothesized that differences in joint mobility 
evolution could be related to differences in glycemic control. Few studies analyze this 
evolution issue and its relation with other parameters. One study concluded that higher HbA1c 
concentrations are predictive for progression of LJM (28). The possibility of 
regression/improvement of LJM is also rarely addressed. Only some case reports have shown 
an improvement and even a complete resolution of LJM along with a decrease in HbA1c values 
(8; 30). In our study, we had similar findings: patients with progression of their initial limitation 
had poorer glycemic control during the follow-up period than patients whose limitation has 
improved or at least didn’t progressed; these findings appeared to be independent of the initial 
stage’s severity. However, the extent to which an improvement in individual glycemic control 
would lead to an improvement of LJM or at least could avoid its progression and, on the other 
hand, a worsening would be responsible for the progression couldn’t be clarified: patients who 
progressed to a severer stage had higher HbA1c levels in the follow-up period compared with 
before in the same way that patients who regressed or maintained the same limitation had lower 
HbA1c levels but differences between the two time periods weren’t significant so we can’t prove 
these associations. One explanation for this could be that the degree of glycemic control is 
more important than its improvement/worsening in LJM evolution; still, we believe that a 
change in glycemic control can influence LJM evolution.    
We didn’t detect any significant differences in the prevalence of retinopathy or 
albuminuria between patients with or without LJM and neither between the different evolution 
groups. Moreover, there was no significant risk for the presence of these complications in 
patients with LJM. In spite of our results, several studies have shown that LJM is significantly 
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associated with both retinopathy and nephropathy in type 1 diabetes (4; 18-20).  In a study, the 
presence of LJM conferred a more than 3-fold increased risk of having microvascular 
complications (18); a prospective study also concluded that the onset of LJM is associated with 
a 1.9-fold greater risk of developing microalbuminuria (16). Based on these findings, some 
authors consider that LJM may be an indicator of the risk of developing these complications 
while others suggest that in spite of the association, LJM cannot be used as a predictor (25). 
We are aware of the several limitations of our study. The small size of our final sample 
is an important limitation since it may not only limit generalizations of our results but also 
contribute to the lack of significance of some comparisons. The strict selection criteria and the 
fact that our sample belongs to a specific clinic population could introduce some selection bias 
and also limit generalizations but, on the other hand, reduced the variability of the sample and 
the influence of diabetes duration, age and puberty. A further potential bias is that a different 
observer undertook 2013 assessments of LJM what could introduce some inter-observer 
variability. This variability could also account for the observed possibility of LJM evolution. 
To attenuate this possible bias, the same evaluation methods were carefully followed by both 
examiners, the abovementioned LJM definition was used and regression and no-evolution 
groups were grouped for statistical analyzes. In spite of these limitations, we would like to 
highlight the importance of having the same single observer for all the assessments performed 
within the same year. Furthermore, this is one of the few studies which describes the 
longitudinal evolution of LJM and its association with glycemic control.  
In summary, severer stages and progression of hand joint limitation are associated with 
poorer glycemic control in type 1 diabetic adolescents and young adults. Current literature 
supports that microvascular complications are also associated to chronic hyperglycemia (1) and 
to LJM (4; 18-20), so we can suppose that a better glycemic control would prevent and delay 
both LJM and microvascular complications and that LJM’s assessment could alert the 
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physician to the likely presence of retinopathy and nephropathy (8). This evaluation would not, 
however, substitute their annual screening (16) but could maybe justify doing it sooner than 
the 5-years of diabetes duration actually defined by the current guidelines (23), especially in 
pubertal/young adults patients with severe limitation. LJM assessment can be easily done 
without time-consuming examinations and so should be a part of the follow-up routine of type 
1 diabetic patients (8). Nevertheless, larger longitudinal studies with repeated evaluations of 
LJM using a standardized method are fundamental to evaluate its clinical course, evolution and 
relation with microvascular complications more fully.  
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TABLES 
 
Table 1 - Demographic and clinical characteristics of the sample at the beginning of the study 
(2007) 
 
 
Data are expressed as means (SD) or median (range) unless stated otherwise. * Mean 
of all values recorded on patient’s medical files until 2007 
 
 
 
 
 
 
 
 
 
 
 
Sample size (n) 26  
Gender (M/F) 14/12 
Age (years) 14.9 ± 1.6 
Age of diabetes diagnosis  (years) 7.1 ± 3.1 
Duration of diabetes (years) 7.5 (5-14) 
HbA1c (%)* 9.3 ± 1.4 
HbA1c (mmol/mol) 78 ± 14.2 
Patients with retinopathy (n) 0 
Patients with albuminuria (n) 2  
19 
 
Table 2 - Characteristics of Limited Joint Mobility evolution groups 
 
 
Data are expressed as means (SD) or median (range) for the total duration of follow-up. * Mean of all 
values recorded during the 6-years follow-up period. † New cases during the follow-up time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Regression/No-evolution Progression p-value 
Frequency (n/%) 18 (69%) 8 (31%)  
Gender (M/F) 9/9 5/3 0.7 
Duration of diabetes (years) 13.5 (11-20) 13.0 (11-18) 0.8 
HbA1c (%)* 8.6 (±1.2) 9.8 (±1.3) 0.03 
HbA1c (mmol/mol) 70 ± 13.1 84 (±14.2)  
Retinopathy (n/%) † 6 (33.3%) 4 (50%) 0.7 
Albuminuria (n/%) † 2 (11.1%) 3 (37.5%) 0.3 
20 
 
Table 3 – Characteristics of the sample comparing all subjects with and without Limited Joint 
Mobility 
 
 
Data are expressed as means (SD) or median (range) for the total duration of the disease. * Mean of 
all values recorded until 2013. † Total of cases for the total duration of the disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 With LJM Without LJM p-value 
Frequency (n/%) 22 (85%) 4 (15%)  
Gender (M/F) 12/10 2/2 1.0 
Duration of diabetes (years) 12.5 (11-18) 17 (11-20) 0.1 
HbA1c (%)* 9.2 (±1.2) 8.7 (±0.7) 0.4 
HbA1c (mmol/mol)    
Retinopathy (n/%) † 9 (41%) 1 (25%) 1.0 
Albuminuria (n/%) † 6 (27%) 1 (25%) 1.0 
21 
 
FIGURES 
 
 
 
Figure 1 Evolution of LMJ during the follow-up time for each initial stage. 
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software for any indication of improper manipulation. Cases of questionable or inappropriate image 
alterations will be referred to the Association’s Subcommittee on Ethical Scientific Publications (ESP). 
The ESP may request the original data from the authors for comparison to the prepared figures. If the 
authors fail to provide the original data, the acceptance of the manuscript will be revoked. Cases of 
deliberate misrepresentation of data will result in revocation of acceptance, and will be reported to the 
corresponding author's home institution and/or funding agency as appropriate. For examples of what 
constitutes improper digital manipulation (as well as other forms of scientific misconduct), ADA 
encourages authors to refer to the 2006 editorial by the Journal of Clinical Investigation titled “Stop 
Misbehaving!” In addition, authors are encouraged to refer to Adobe’s white paper on using Photoshop 
CS3 Extended in biomedical imaging. The paper provides useful information on maintaining image 
integrity, editing nondestructively, and the medical and scientific image workflow. 
 
 
